Emerging treatments
Janus kinase (JAK) inhibitors
JAK2 inhibitors may be particularly effective in those with intractable pruritus, severe constitutional symptoms, or marked splenomegaly. Ruxolitinib, a JAK 1/2 inhibitor, may potentially have a role in treating patients with essential thrombocythaemia (ET) with significant symptom burden who exhaust, or are intolerant to, existing treatment options.[38][66] Results from a phase II randomised trial comparing ruxolitinib with best available therapy in patients with ET resistant/intolerant to hydroxycarbamide suggest some clinical efficacy, with improved symptom control.[67] Ruxolitinib was, however, not superior to current second-line treatment.[67]
Use of this content is subject to our disclaimer